Related Experiment Video
Updated: Jun 21, 2025
10:19
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
1.2K
FLT3/CD99 Bispecific Antibody-Based Nanoparticles for Acute Myeloid Leukemia
Atham Ali1, Alvin Phan2, Vijaya Vaikari1
1Department of Clinical Pharmacy, USC School of Pharmacy, University of Southern California, Los Angeles, California.
Cancer Research Communications
|July 15, 2024
Summary
A new dual-targeting therapy for acute myeloid leukemia (AML) combines targeting of FLT3 and CD99. This novel approach shows promise in reducing leukemia burden and improving survival in preclinical models of FLT3-ITD AML.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Cluster of differentiation 99 (CD99) is upregulated in acute myeloid leukemia (AML), particularly in FLT3-ITD AML.
- Previous studies utilized elastin-like polypeptides fused with single-chain antibodies to target FLT3 or CD99 individually, showing efficacy in AML models.
Purpose of the Study:
- To develop and evaluate a novel bispecific Co-Assembled construct targeting both CD99 and FLT3.
- To assess the anti-leukemia activity of this dual-targeting construct in preclinical models of FLT3-ITD AML.
Main Methods:
- Development of a Co-Assembled formulation capable of binding to both CD99 and FLT3.
- Preclinical testing in FLT3-ITD AML cell lines, primary blasts, and mouse models.
Main Results:
- The dual-targeting Co-Assembled construct demonstrated significant cytotoxic effects on AML cells.
- Reduced leukemia burden and prolonged survival were observed in FLT3-ITD AML mouse models.
Conclusions:
- A novel therapeutic strategy targeting both CD99 and FLT3 shows significant potential for treating FLT3-ITD AML.
- This dual-targeting approach offers a promising new avenue for AML therapy.
